Durect announced that the U.S. FDA has granted Breakthrough Therapy designation to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRRX:
- Durect reports Q1 EPS (25c) vs. (52c) last year
- DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
- Options Volatility and Implied Earnings Moves Today, May 13, 2024
- DRRX Upcoming Earnings Report: What to Expect?
- DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update